Centre National De La Recherche Scientifique

Immupharma France Sa

Institut Pasteur

Biomerieux Sa

Biomerieux, Inc.

Pasteur Sanofi Diagnostics

Neomps

Cnrs

Immupharma Sa

Jean-Paul Briand

Gilles Guichard

Sylviane Muller

Vincent Semetey

Robert H Zimmer

Elisa Rodriguez, Legal Representative

Marie-Christine Galas-Rodriguez, Legal Representative

Bernard Krust

Ara G Hovanessian

Jose P Courty

Romain Rodriguez, Legal Representative

Pierre Rodriguez, Legal Representative

Marc Van Regenmortel

Gilles Francois Roger Guichard

Patrick Neuberg

Aude Violette

Elias Said

Josette Svab

Fanny Sylvie Michele Monneaux

Jean Neimark

Yamina Hamma

Robert Zimmer

Arnaud-Pierre Schaffner

Samira Barakat

Jean-Christophe Weber

Marc Regenmortel

Slyviane Muller

Serge Plaue

David Limal

Jean Gerard Guillet

Fanny Monneaux

Marc (decede) Rodriguez

Marc (deceased) Rodriguez

Gilles Francois Guichard

Ara Hovanessian

Elias c/o Mr Said Nicolas Said

The present invention relates to a peptide, or a salt thereof, comprising or consisting of the amino acid sequence IHMVYSKRSGKPRGYAFIEY, comprising one or more post-translational modifications, for the treatment, prevention or amelioration of a hyper autophagy-related autoimmune disease or disorder.

Methods of treating chronic inflammatory diseases

The present invention relates to a peptide, or a salt thereof, comprising or consisting of the amino acid sequence IHMVYSKRSGKPRGYAFIEY, comprising one or more post-translational modifications.

Modified peptides and their use for treating autoimmune diseases

Derivatives of the peptide corresponding to the sequence RIHMVYSKRSGKPRGYAFIEY (SEQ ID NO: 1), pharmaceutical compositions, and methods of use thereof are provided.

Phosphorylated derivatives of a U1-70K peptide and their use in the treatment of autoimmune pathologies

The present invention relates to peptides, referred to as CBD-1, CBD-2, CBM-1/TH-1, CBM-1/TH-2, CBM-2/TH-1, CBM-2/TH-2 and C-20 peptides, which are antigenic and elicit a protective immune response against HIV infection. Compositions, pharmaceutical compositions and vaccines comprising these antigenic peptides are also encompassed by the present invention, as well as neutralizing antibodies which inhibit infection of primary CD4+ T lymphocytes by various HIV isolates. Methods for diagnosis of HIV are also disclosed.

Synthetic peptide vaccines for HIV: the CBD epitope as an effective immunogen to elicit broadly neutralizing antibodies against HIV

The present invention relates to compositions and methods for producing therapeutic oligomeric compounds. In one aspect the invention relates to methods for administering the oligomeric compounds for the treatment and prevention of disease, for example, a fungal infection, bacterial infection, or cancer, in a mammal. In particular, the invention relates to medicaments comprising various novel oligomeric compounds and pharmaceutically acceptable salts thereof. The compounds of the invention may optionally be administered with at least one of a pharmaceutically acceptable excipient, pharmacologically active agent or a combination thereof.

Hybrid oligomers, their preparation process and pharmaceutical compositions containing them

A method for treating a cytotoxic disease by administrating compounds having a general formula X-(A)n-Y, wherein: n varies between 6 and 20; X denotes a hydrogen atom, an RaCO, RaOCO, RaNHCO or RaSO2 group, Ra being an alkyl, alkenyl, alkynyl, aryl, aralkyl, heteroaryl group, the groups being substituted or not, on condition that X is different from H when n is equal to 6; A denotes either a group having formula (I) or (II), wherein Ri is a hydrogen atom, an amino acid side chain, an alkyl, alkenyl, alkynyl, aryl, aralkyl or heteroaryl group, said groups being substituted or not, i being an integer of between 1 and n; Y is an NRbRc, Rb and Rc group having the same meaning as given earlier for Ra.

Urea oligomers, their preparation process and pharmaceutical compositions containing them

Compounds having a general formula X-(A)n-Y, wherein: n varies between 6 and 20; X denotes a hydrogen atom, an RaCO, RaOCO, RaNHCO or RaSO2 group, Ra being an alkyl, alkenyl, alkynyl, aryl, aralkyl, heteroaryl group, the groups being substituted or not, on condition that X is different from H when n is equal to 6; A denotes either a group having formula (I) or (II), wherein Ri is a hydrogen atom, an amino acid side chain, an alkyl, alkenyl, alkynyl, aryl, aralkyl or heteroaryl group, said groups being substituted or not, i being an integer of between 1 and n; Y is an NRbRc, Rb and Rc group having the same meaning as given earlier for Ra. The compounds are used for the preparation of medicaments that are intended to treat bacterial, fungal or cytotoxic diseases and, in particular, fungal infections, such as aspergillosis and candidiasis, and resistant bacterial infections.

Urea oligomers, the preparation method thereof and pharmaceutical composition containing same

The invention concerns a pseudopeptide of at least 6 amino acids comprising at least a unit selected among the general formulae (I) and/or (II) wherein: R, Rand Reach independently of one another represent a side-chain of amino acids and can be identical or different; X represents an oxygen or sulphur atom. The invention also concerns its synthesis process, a reagent containing it, a detection kit comprising such a reagent, a method for detecting an antigen or an antibody using said pseudopeptide, and antibody or and anti-idiotype and finally a therapeutic composition.

Pseudopeptide, synthesis method, reagent and applications

A method for preparing cyclic urea compounds from at least an activated carbamic acid derivative containing an unprotected primary or secondary amine function, includes a cyclization step which consists in a reaction between the primary or secondary amine function and the carbamic acid function of the carbamic acid derivative(s).

Cyclic urea compounds and preparation thereof

Stabilized activated derivatives of carbamic acid, their process of preparation and their use for the preparation of ureas

The present invention relates to retro peptides, as well as antibodies thereto, and to their uses, chiefly in the field of preparation of pharmaceutical compositions, in particular vaccines, and for in vitro diagnosis of various pathologies.

Retro peptides, antibodies thereto and their uses for vaccination and in vitro diagnosis

Process for the preparation of stable activated derivatives of carbamic acid, comprising at least one protected amino group and an activated carbamic acid function, from an amino acid derivative in which the amino group is protected. The process includes: a) a step of transformation of the &#x2014;COOH group of the amino acid derivative into a &#x2014;CONgroup to obtain an acyl azide; b) a step of transformation of the &#x2014;CONgroup of the acyl azide into a &#x2014;NCO group to obtain an isocyanate; c) a step of treating the isocyanate to obtain a stable derivative of carbamic acid.

Growing community of inventors

Strasbourg, France

Jean-Paul Briand